GH vs TMO
GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum. TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries.
Side-by-side fundamentals
| Metric | GH | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $152.35 | $559.53 | |
| Market cap as of 2026-08-01 | $20.4B | $207.9B | |
| P/E as of 2026-08-01 | n/a | 30.55 | |
| PEG as of 2026-08-01 | -9.46 | 3.39 | GH lower |
| Net margin as of 2026-08-01 | -40.1% | +15.0% | TMO higher |
| Gross margin as of 2026-08-01 | +64.9% | +40.9% | GH higher |
| Operating margin as of 2026-08-01 | -42.7% | +17.6% | TMO higher |
| ROE as of 2026-08-01 | -246.6% | +13.3% | TMO higher |
| ROA as of 2026-08-01 | -26.5% | +6.3% | TMO higher |
| Debt / equity as of 2026-08-01 | 16.78 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-01 | +39.6% | +7.2% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | -0.3% | GH higher |
| Dividend yield as of 2026-08-01 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-01 | 1.62 | 0.85 | |
| 1-year return as of 2026-07-30 close | +237.1% | +17.0% | GH higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.